{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:17:20Z","timestamp":1792793840757,"version":"4.5.0"},"reference-count":103,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,20]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      Pulmonary arterial hypertension (PAH) is a rare, progressive disorder defined by elevated pulmonary arterial pressure and vascular resistance, ultimately leading to right ventricular failure and premature death. Once considered a disease of pure vasoconstriction, PAH is now recognized as a complex vasculopathy involving endothelial dysfunction, inflammation, metabolic dysregulation, and genetic susceptibility. The pulmonary vasculature is dynamically narrowed by vasoconstriction, structurally obstructed by smooth muscle and endothelial proliferation, and pathologically stiffened by fibrosis and extracellular matrix deposition. Multiple cell types including endothelial cells, smooth muscle cells, fibroblasts, and immune cells contribute to this remodeling process. At the molecular level, hyperproliferative, apoptosis-resistant phenotypes emerge through mitochondrial dysfunction, oxidative stress, and endothelial-to-mesenchymal transition, which together drive a Warburg-like metabolic shift favoring glycolysis over oxidative phosphorylation. Chronic immune activation, characterized by cytokine release, T-cell and macrophage infiltration, and disrupted immune regulation, further amplifies vascular injury. Genetic studies have identified mutations in\n                      <jats:italic toggle=\"yes\">BMPR2, TBX4, SOX17<\/jats:italic>\n                      , and other regulators of the bone morphogenic protein (BMP)\/transform\u00ading growth factor-\u03b2 (TGF-\u03b2) pathway as key contributors to heritable and idiopathic forms of PAH, highlighting impaired endothelial repair and aberrant signaling as central mechanisms. Recent translational breakthroughs have yielded novel therapeutic strategies beyond traditional vasodilators. Agents targeting the BMP\/TGF-\u03b2 axis (e.g., sotatercept), growth factor signaling (seralutinib), inflammatory pathways (tocilizumab, rituximab), and metabolic remodeling (pyruvate dehydrogenase kinases [PDK] and fatty acid oxidation [FAO] modulators) are redefining treatment paradigms. Concurrently, large-scale multi-omics initiatives such as PVDOMICS and PHOENIKS enable deep phenotyping, which unravels molecular endotypes and informs precision medicine approaches. This review summarizes the pathophysiology of PAH and the ongoing clinical trials in the PAH field.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000004137","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:00:10Z","timestamp":1781766010000},"page":"2070-2083","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Pulmonary arterial hypertension from a translational perspective: Bridging pathophysiology and treatment"],"prefix":"10.1097","volume":"139","author":[{"given":"Taeil","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Cardiology, Gil Medical Center, Gachon University College of Medicine, Incheon 21565, Republic of Korea"},{"name":"Gachon Cardiovascular Research Institute, Gachon University, Incheon 21565, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wook-Jin","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Gil Medical Center, Gachon University College of Medicine, Incheon 21565, Republic of Korea"},{"name":"Gachon Cardiovascular Research Institute, Gachon University, Incheon 21565, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"R1-20260720","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMra2000348","article-title":"Pulmonary arterial hypertension","volume":"385","author":"Hassoun","year":"2021","journal-title":"N Engl J Med"},{"key":"R2-20260720","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"R3-20260720","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S2213-2600(24)00295-9","article-title":"Global, regional, and national burden of pulmonary arterial hypertension, 1990\u20132021: A systematic analysis for the Global Burden of Disease Study 2021","volume":"13","year":"2025","journal-title":"Lancet Respir Med"},{"key":"R4-20260720","article-title":"Incidence and mortality trend of congenital heart disease at the global, regional, and national level, 1990\u20132017","volume":"99","author":"Wu","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"R5-20260720","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4070\/kcj.2022.0231","article-title":"Epidemiology of PAH in Korea: An analysis of the National Health Insurance Data, 2002\u20132018","volume":"53","author":"Jang","year":"2023","journal-title":"Korean Circ J"},{"key":"R6-20260720","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1097\/CM9.0000000000003559","article-title":"Burden of pulmonary arterial hypertension in Asia from 1990 to 2021: Findings from Global Burden of Disease Study 2021","volume":"138","author":"Huang","year":"2025","journal-title":"Chin Med J"},{"key":"R7-20260720","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3904\/kjim.2019.185","article-title":"Current status of pulmonary arterial hypertension in Korea","volume":"34","author":"Jang","year":"2019","journal-title":"Korean J Intern Med"},{"key":"R8-20260720","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024969","article-title":"Mortality in pulmonary arterial hypertension in the modern era: Early insights from the pulmonary hypertension association registry","volume":"11","author":"Chang","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"R9-20260720","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: Results from a national registry","volume":"173","author":"Humbert","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"R10-20260720","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1183\/09031936.00101211","article-title":"Survival in pulmonary hypertension in Spain: Insights from the Spanish registry","volume":"40","author":"Escribano-Subias","year":"2012","journal-title":"Eur Respir J"},{"key":"R11-20260720","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2022-000137","article-title":"Pathophysiology and new advances in pulmonary hypertension","volume":"2","author":"Bousseau","year":"2023","journal-title":"BMJ Med"},{"key":"R12-20260720","article-title":"The role of immune cells and inflammation in pulmonary hypertension: Mechanisms and implications","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Immunol"},{"key":"R13-20260720","doi-asserted-by":"crossref","DOI":"10.1177\/2045893217752912","article-title":"Endothelial dysfunction in pulmonary arterial hypertension: An evolving landscape (2017 Grover Conference Series)","volume":"8","author":"Ranchoux","year":"2018","journal-title":"Pulm Circ"},{"key":"R14-20260720","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1172\/JCI60658","article-title":"Molecular pathogenesis of pulmonary arterial hypertension","volume":"122","author":"Rabinovitch","year":"2012","journal-title":"J Clin Invest"},{"key":"R15-20260720","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.vph.2008.06.003","article-title":"Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension","volume":"49","author":"Humbert","year":"2008","journal-title":"Vascul Pharmacol"},{"issue":"Suppl 1","key":"R16-20260720","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1186\/1755-1536-5-S1-S7","article-title":"Molecular mechanisms of endothelial to mesenchymal cell transition (EndoMT) in experimentally induced fibrotic diseases","volume":"5","author":"Piera-Velazquez","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"key":"R17-20260720","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1161\/CIRCULATIONAHA.114.008750","article-title":"Endothelial-to-mesenchymal transition in pulmonary hypertension","volume":"131","author":"Ranchoux","year":"2015","journal-title":"Circulation"},{"key":"R18-20260720","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.ajpath.2015.03.019","article-title":"Endothelial to mesenchymal transition contributes to endothelial dysfunction in pulmonary arterial hypertension","volume":"185","author":"Good","year":"2015","journal-title":"Am J Pathol"},{"key":"R19-20260720","doi-asserted-by":"crossref","first-page":"L118","DOI":"10.1152\/ajplung.00296.2017","article-title":"Isolation and characterization of endothelial-to-mesenchymal transition cells in pulmonary arterial hypertension","volume":"314","author":"Suzuki","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"R20-20260720","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1164\/rccm.202302-0327SO","article-title":"Pulmonary hypertension: A contemporary review","volume":"208","author":"Johnson","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"R21-20260720","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102797","article-title":"Metabolic reprogramming, oxidative stress, and pulmonary hypertension","volume":"64","author":"Pokharel","year":"2023","journal-title":"Redox Biology"},{"key":"R22-20260720","article-title":"Combination of dichloroacetate and atorvastatin regulates excessive proliferation and oxidative stress in pulmonary arterial hypertension development via p38 signaling","volume":"2020","author":"Li","year":"2020","journal-title":"Oxid Med Cell Longev"},{"key":"R23-20260720","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/01.RES.0000145360.16770.9f","article-title":"Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis","volume":"95","author":"McMurtry","year":"2004","journal-title":"Circ Res"},{"key":"R24-20260720","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00109-012-0982-0","article-title":"FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: Therapeutic benefits of dichloroacetate","volume":"91","author":"Piao","year":"2013","journal-title":"J Mol Med"},{"key":"R25-20260720","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.3390\/cells9112338","article-title":"Perivascular inflammation in pulmonary arterial hypertension","volume":"9","author":"Hu","year":"2020","journal-title":"Cells"},{"key":"R26-20260720","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1164\/rccm.201201-0164OC","article-title":"Modern age pathology of pulmonary arterial hypertension","volume":"186","author":"Stacher","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"R27-20260720","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.4049\/jimmunol.1100479","article-title":"Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension","volume":"187","author":"Li","year":"2011","journal-title":"J Immunol"},{"key":"R28-20260720","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/247372","article-title":"Effect of Th17 and Treg axis disorder on outcomes of pulmonary arterial hypertension in connective tissue diseases","volume":"2014","author":"Gaowa","year":"2014","journal-title":"Mediators Inflamm"},{"key":"R29-20260720","first-page":"4","article-title":"The dynamic duo-inflammatory M1 macrophages and Th17 cells in rheumatic diseases","volume":"1","author":"Li","year":"2013","journal-title":"J Orthop Rheumatol"},{"key":"R30-20260720","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.3892\/mmr.2014.3106","article-title":"Regulatory T cells protect against hypoxia-induced pulmonary arterial hypertension in mice","volume":"11","author":"Chu","year":"2015","journal-title":"Mol Med Rep"},{"key":"R31-20260720","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1372959","article-title":"Single cell transcriptomic analyses reveal diverse and dynamic changes of distinct populations of lung interstitial macrophages in hypoxia-induced pulmonary hypertension","volume":"15","author":"Kumar","year":"2024","journal-title":"Front Immunol"},{"key":"R32-20260720","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.4049\/jimmunol.1701287","article-title":"Inflammatory macrophage expansion in pulmonary hypertension depends upon mobilization of blood-borne monocytes","volume":"200","author":"Florentin","year":"2018","journal-title":"J Immunol"},{"key":"R33-20260720","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006674","article-title":"Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension","volume":"5","author":"Tian","year":"2013","journal-title":"Sci Transl Med"},{"key":"R34-20260720","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1164\/rccm.202009-3481OC","article-title":"Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension: A multicenter, double-blind, randomized, placebo-controlled trial","volume":"204","author":"Zamanian","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"R35-20260720","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fmed.2018.00217","article-title":"The role of neutrophils and neutrophil elastase in pulmonary arterial hypertension","volume":"5","author":"Taylor","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"R36-20260720","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5483\/BMBRep.2014.47.1.285","article-title":"Role of vascular smooth muscle cell in the inflammation of atherosclerosis","volume":"47","author":"Lim","year":"2014","journal-title":"BMB reports"},{"key":"R37-20260720","first-page":"275","article-title":"Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension","volume":"144","author":"Tuder","year":"1994","journal-title":"Am J Pathol"},{"key":"R38-20260720","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1161\/CIRCRESAHA.118.314555","article-title":"Metabolic syndrome exacerbates pulmonary hypertension due to left heart disease","volume":"125","author":"Ranchoux","year":"2019","journal-title":"Circ Res"},{"key":"R39-20260720","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/CIRCULATIONAHA.109.933762","article-title":"Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension","volume":"122","author":"Soon","year":"2010","journal-title":"Circulation"},{"key":"R40-20260720","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1164\/ajrccm.151.5.7735624","article-title":"Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension","volume":"151","author":"Humbert","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"R41-20260720","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1172\/JCI120847","article-title":"Mitochondrial metabolism in pulmonary hypertension: Beyond mountains there are mountains","volume":"128","author":"Culley","year":"2018","journal-title":"J Clin Invest"},{"key":"R42-20260720","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1161\/CIRCRESAHA.120.316443","article-title":"Epigenetic metabolic reprogramming of right ventricular fibroblasts in pulmonary arterial hypertension: A pyruvate dehydrogenase kinase-dependent shift in mitochondrial metabolism promotes right ventricular fibrosis","volume":"126","author":"Tian","year":"2020","journal-title":"Circ Res"},{"key":"R43-20260720","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12931-018-0776-1","article-title":"Recurrent inhibition of mitochondrial complex III induces chronic pulmonary vasoconstriction and glycolytic switch in the rat lung","volume":"19","author":"Rafikova","year":"2018","journal-title":"Respir Res"},{"key":"R44-20260720","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.redox.2015.07.016","article-title":"Complex I dysfunction underlies the glycolytic switch in pulmonary hypertensive smooth muscle cells","volume":"6","author":"Rafikov","year":"2015","journal-title":"Redox Biol"},{"key":"R45-20260720","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1161\/CIRCULATIONAHA.109.916098","article-title":"Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: A basis for excessive cell proliferation and a new therapeutic target","volume":"121","author":"Archer","year":"2010","journal-title":"Circulation"},{"key":"R46-20260720","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180455","article-title":"Contribution of reactive oxygen species to the pathogenesis of pulmonary arterial hypertension","volume":"12","author":"Jernigan","year":"2017","journal-title":"PLoS One"},{"key":"R47-20260720","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1126\/science.1219855","article-title":"Mitochondrial fission, fusion, and stress","volume":"337","author":"Youle","year":"2012","journal-title":"Science"},{"key":"R48-20260720","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1091\/mbc.e02-10-0657","article-title":"Constriction and Dnm1p recruitment are distinct processes in mitochondrial fission","volume":"14","author":"Legesse-Miller","year":"2003","journal-title":"Mol Biol Cell"},{"key":"R49-20260720","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1016\/j.bbadis.2017.07.018","article-title":"Inhibition of mitochondrial fission prevents hypoxia-induced metabolic shift and cellular proliferation of pulmonary arterial smooth muscle cells","volume":"1863","author":"Parra","year":"2017","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"R50-20260720","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1161\/CIRCRESAHA.111.263848","article-title":"Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension","volume":"110","author":"Marsboom","year":"2012","journal-title":"Circ Res"},{"key":"R51-20260720","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00109-017-1522-8","article-title":"Ischemia-induced Drp1 and Fis1-mediated mitochondrial fission and right ventricular dysfunction in pulmonary hypertension","volume":"95","author":"Tian","year":"2017","journal-title":"J Mol Med (Berl)"},{"key":"R52-20260720","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1083\/jcb.200809125","article-title":"Parkin is recruited selectively to impaired mitochondria and promotes their autophagy","volume":"183","author":"Narendra","year":"2008","journal-title":"J Cell Biol"},{"key":"R53-20260720","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1161\/ATVBAHA.114.304865","article-title":"Endothelial uncoupling protein 2 regulates mitophagy and pulmonary hypertension during intermittent hypoxia","volume":"35","author":"Haslip","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R54-20260720","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jacc.2011.02.057","article-title":"Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: Clinical prevalence, outcomes, and mechanistic insights","volume":"58","author":"Rhodes","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R55-20260720","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1086\/682217","article-title":"Intravenous iron therapy in patients with idiopathic pulmonary arterial hypertension and iron deficiency","volume":"5","author":"Ruiter","year":"2015","journal-title":"Pulm Circ"},{"key":"R56-20260720","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ijcard.2014.04.233","article-title":"Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: A pilot study","volume":"175","author":"Viethen","year":"2014","journal-title":"Int J Cardio"},{"key":"R57-20260720","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.bbamcr.2014.09.009","article-title":"Iron\u2013sulfur cluster biogenesis in mammalian cells: New insights into the molecular mechanisms of cluster delivery","volume":"1853","author":"Maio","year":"2015","journal-title":"Biochim Biophys Acta, Mol Cell Res"},{"key":"R58-20260720","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3390\/cells10020477","article-title":"Iron deficiency in pulmonary arterial hypertension: A deep dive into the mechanisms","volume":"10","author":"Quatredeniers","year":"2021","journal-title":"Cells"},{"key":"R59-20260720","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.bbamcr.2012.08.014","article-title":"Targeting mitochondrial oxidative metabolism as an approach to treat heart failure","volume":"1833","author":"Fillmore","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"R60-20260720","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1105565","article-title":"Acquired disorders of mitochondrial metabolism and dynamics in pulmonary arterial hypertension","volume":"11","author":"Breault","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"R61-20260720","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00109-011-0804-9","article-title":"Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: Exploiting Randle\u2019s cycle","volume":"90","author":"Fang","year":"2012","journal-title":"J Mol Med (Berl)"},{"key":"R62-20260720","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1086\/682427","article-title":"Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: A pilot study","volume":"5","author":"Khan","year":"2015","journal-title":"Pulm Circ"},{"key":"R63-20260720","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00109-009-0524-6","article-title":"The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: Resuscitating the hibernating right ventricle","volume":"88","author":"Piao","year":"2010","journal-title":"J Mol Med (Berl)"},{"key":"R64-20260720","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.jacc.2005.02.065","article-title":"Increased [18F] fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenol","volume":"45","author":"Oikawa","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R65-20260720","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00109-013-1059-4","article-title":"A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension","volume":"91","author":"Sutendra","year":"2013","journal-title":"J Mol Med (Berl)"},{"key":"R66-20260720","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1161\/CIRCRESAHA.122.320084","article-title":"New mutations and pathogenesis of pulmonary hypertension: Progress and puzzles in disease pathogenesis","volume":"130","author":"Aldred","year":"2022","journal-title":"Circ Res"},{"key":"R67-20260720","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/path.2261","article-title":"Regulation of bone morphogenetic protein signalling in human pulmonary vascular development","volume":"214","author":"Southwood","year":"2008","journal-title":"J Pathol"},{"key":"R68-20260720","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1161\/CIRCRESAHA.122.321554","article-title":"BMPR2 mutation and metabolic reprogramming in pulmonary arterial hypertension","volume":"132","author":"Cuthbertson","year":"2023","journal-title":"Circ Res"},{"key":"R69-20260720","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1093\/hmg\/dds073","article-title":"BMPR-II deficiency elicits pro-proliferative and anti-apoptotic responses through the activation of TGF\u03b2-TAK1-MAPK pathways in PAH","volume":"21","author":"Nasim","year":"2012","journal-title":"Hum Mol Genet"},{"key":"R70-20260720","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01609-2018","article-title":"Germline BMP9 mutation causes idiopathic pulmonary arterial hypertension","volume":"53","author":"Wang","year":"2019","journal-title":"Eur Respir J"},{"key":"R71-20260720","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3390\/biom10091261","article-title":"Implication of potassium channels in the pathophysiology of pulmonary arterial hypertension","volume":"10","author":"Le Ribeuz","year":"2020","journal-title":"Biomolecules"},{"key":"R72-20260720","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002866","article-title":"Multiple roles and interactions of Tbx4 and Tbx5 in development of the respiratory system","volume":"8","author":"Arora","year":"2012","journal-title":"PLoS Genet"},{"key":"R73-20260720","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13073-018-0566-x","article-title":"Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease","volume":"10","author":"Zhu","year":"2018","journal-title":"Genome Med"},{"key":"R74-20260720","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01370-2024","article-title":"Genetics and precision genomics approaches to pulmonary hypertension","volume":"64","author":"Austin","year":"2024","journal-title":"Eur Respir J"},{"key":"R75-20260720","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2023.100925","article-title":"Defining the clinical validity of genes reported to cause pulmonary arterial hypertension","volume":"25","author":"Welch","year":"2023","journal-title":"Genet Med"},{"key":"R76-20260720","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1016\/S0140-6736(22)01601-4","article-title":"The evolving landscape of pulmonary arterial hypertension clinical trials","volume":"400","author":"Weatherald","year":"2022","journal-title":"Lancet"},{"key":"R77-20260720","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01030-2019","article-title":"Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: Results from a phase 2 randomised, parallel group, placebo-controlled trial","volume":"54","author":"Torres","year":"2019","journal-title":"Eur Respir J"},{"key":"R78-20260720","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01110-2024","article-title":"MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: The INSIGNIA-PAH study","volume":"64","author":"Humbert","year":"2024","journal-title":"Eur Respir J"},{"key":"R79-20260720","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01899-2018","article-title":"Genetics and genomics of pulmonary arterial hypertension","volume":"53","author":"Morrell","year":"2019","journal-title":"Eur Respir J"},{"key":"R80-20260720","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N Engl J Med"},{"key":"R81-20260720","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N Engl J Med"},{"key":"R82-20260720","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01347-2022","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"key":"R83-20260720","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa2415160","article-title":"Sotatercept in patients with pulmonary arterial hypertension at high risk for death","volume":"392","author":"Humbert","year":"2025","journal-title":"N Engl J Med"},{"key":"R84-20260720","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1164\/rccm.202502-0344RL","article-title":"Severe hypoxemia and pulmonary capillary dilatations in pulmonary arterial hypertension patients treated with sotatercept","volume":"211","author":"Olsson","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"R85-20260720","article-title":"New therapies in pulmonary arterial hypertension: Recent insights","volume":"19","author":"Guglielmi","year":"2025","journal-title":"Int J Cardiol Congenit Heart Dis"},{"key":"R86-20260720","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1161\/CIRCRESAHA.111.300483","article-title":"Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradation","volume":"112","author":"Long","year":"2013","journal-title":"Circ Res"},{"key":"R87-20260720","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1186\/s13063-024-08485-z","article-title":"StratosPHere 2: Study protocol for a response-adaptive randomised placebo-controlled phase II trial to evaluate hydroxychloroquine and phenylbutyrate in pulmonary arterial hypertension caused by mutations in BMPR2","volume":"25","author":"Deliu","year":"2024","journal-title":"Trials"},{"key":"R88-20260720","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1164\/rccm.200707-1037OC","article-title":"Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension","volume":"178","author":"Perros","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"R89-20260720","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized IMPRES study","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"},{"key":"R90-20260720","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S2213-2600(24)00072-9","article-title":"Seralutinib in adults with pulmonary arterial hypertension (TORREY): A randomised, double-blind, placebo-controlled phase 2 trial","volume":"12","author":"Frantz","year":"2024","journal-title":"Lancet Respir Med"},{"key":"R91-20260720","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02463-2020","article-title":"Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension","volume":"59","author":"Toshner","year":"2022","journal-title":"Eur Respir J"},{"key":"R92-20260720","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12251","article-title":"SATISFY-JP, a phase II multicenter open-label study on Satralizumab, an anti-IL-6 receptor antibody, use for the treatment of pulmonary arterial hypertension in patients with an immune-responsive-phenotype: Study protocol","volume":"13","author":"Tamura","year":"2023","journal-title":"Pulm Circ"},{"key":"R93-20260720","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1053\/j.gastro.2020.11.006","article-title":"Dicarbonyl electrophiles mediate inflammation-induced gastrointestinal carcinogenesis","volume":"160","author":"Gobert","year":"2021","journal-title":"Gastroenterology"},{"key":"R94-20260720","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40360-018-0281-7","article-title":"First-in-human study assessing safety, tolerability, and pharmacokinetics of 2-hydroxybenzylamine acetate, a selective dicarbonyl electrophile scavenger, in healthy volunteers","volume":"20","author":"Pitchford","year":"2019","journal-title":"BMC Pharmacol Toxicol"},{"key":"R95-20260720","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature14620","article-title":"The zinc transporter ZIP12 regulates the pulmonary vascular response to chronic hypoxia","volume":"524","author":"Zhao","year":"2015","journal-title":"Nature"},{"key":"R96-20260720","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.924873","article-title":"An overview of circulating pulmonary arterial hypertension biomarkers","volume":"9","author":"Santos-Gomes","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R97-20260720","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00246-016-1487-3","article-title":"Circulating microRNA as a novel biomarker for pulmonary arterial hypertension due to congenital heart disease","volume":"38","author":"Chen","year":"2017","journal-title":"Pediatr Cardiol"},{"key":"R98-20260720","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1097\/CM9.0000000000001193","article-title":"MicroRNA-98 can serve as a diagnostic marker for congenital heart disease-associated pulmonary artery hypertension","volume":"133","author":"Zhang","year":"2020","journal-title":"Chin Med J"},{"key":"R99-20260720","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.chest.2025.10.031","article-title":"Growth differentiation factor-15 improves prognostic accuracy of risk stratification in pulmonary arterial hypertension","volume":"169","author":"Wang","year":"2026","journal-title":"Chest"},{"key":"R100-20260720","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.chest.2020.07.088","article-title":"United States pulmonary hypertension scientific registry: Baseline characteristics","volume":"159","author":"Badlam","year":"2021","journal-title":"Chest"},{"key":"R101-20260720","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1161\/CIRCRESAHA.117.311737","article-title":"PVDOMICS: A multi-center study to improve understanding of pulmonary vascular disease through phenomics","volume":"121","author":"Hemnes","year":"2017","journal-title":"Circ Res"},{"key":"R102-20260720","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40885-019-0126-8","article-title":"A nationwide multicenter registry and biobank program for deep phenotyping of idiopathic and hereditary pulmonary arterial hypertension in Korea: The PAH platform for deep phenotyping in Korean subjects (PHOENIKS) cohort","volume":"25","author":"Jang","year":"2019","journal-title":"Clin Hypertens"},{"key":"R103-20260720","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1164\/rccm.202203-0537ED","article-title":"Promises and pitfalls of multiomics approaches to pulmonary arterial hypertension","volume":"205","author":"Simpson","year":"2022","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000004137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:01:48Z","timestamp":1784541708000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000004137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":103,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000004137","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"2025-11-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}